HCW Biologics CFO Rebecca Byam acquires 14,235 shares for $19,998.68

HCW Biologics, Inc.

HCW Biologics, Inc.

HCWB

0.00
  • HCW Biologics CFO Rebecca Byam bought 14,235 common shares in a private placement at USD 1.41 per share.
  • Her direct holdings rose to 57,245 shares following the purchase.
  • She also bought 14,235 common stock purchase warrants with a USD 1.28 exercise price, expiring Nov. 22, 2031.
  • Warrant holdings increased to 18,466 following the transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-025474), on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.